Search

Your search keyword '"Baliellas C"' showing total 209 results
Start Over Author "Baliellas C"
209 results on '"Baliellas C"'

7. Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C)

Author

Puigvehi, M, Albillos, A, Viu, A, Hernandez-Guerra, M, Vazquez, IF, Prieto, M, Torras, X, Zabal, JMR, Santamaria, LG, Morillas, R, Diago, M, Moron, BDC, Delgado, M, Bonet, L, Turnes, J, Crespo, J, Baliellas, C, Panero, JLC, Badia-Aranda, E, Pascasio, JM, Moreno, JM, Monterde, VB, Carmona, I, Fernandez-Bermejo, M, Quiles, R, Garcia, PB, Gonzalez-Santiago, JM, Gutierrez, ML, Moreno, JJ, Conejero, MDA, De la Vega, J, Escudero-Garcia, D, Arenas, J, and Carrion, JA

Published
2019

13. «De Novo» Carcinoma after Liver Transplant (L.T.)

Author

Taltavull, T. Casanovas, primary, Baliellas, C., additional, Gili, M. Sánchez, additional, Casanova, A., additional, Benasco, C., additional, Fabregat, J., additional, Rafecas, A., additional, Figueras, J., additional, Gil-Vernet, S., additional, Jaurrieta, E., additional, and Casais, L. A., additional

Published
1996
Full Text
View/download PDF

14. HCV Chronic Infection in HD (Hemodialysed) Candidates to KT (Kidney Transplant). Influence of Virus C Genotypes on Response to IFN Treatment

Author

Taltavull, T. Casanovas, primary, Baliellas, C., additional, Perelló, A., additional, Cervantes, X., additional, Benasco, C., additional, Andrés, E., additional, González, M. T., additional, Gil-Vernet, S., additional, Pérez, J. L., additional, Niubó, J., additional, Casanova, A., additional, and Casais, L. A., additional

Published
1996
Full Text
View/download PDF

19. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C

Author

Fernández I, Muñoz-Gómez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, Arias A, Prieto M, Castells L, Cuervas-Mons V, Hernández O, Crespo J, Calleja JL, Forns X, and Londoño MC

Subjects
Immunosuppressive therapy, Renal transplantation, Direct-acting antivirals, Hepatitis C, Liver transplant
Abstract

Background & Aims: The development of direct-acting antiviral agents (DAAs) is a major step forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the efficacy and tolerability of DAAs in kidney transplant (KT) recipients. Methods: Hepa-C is a Spanish registry of patients treated with DAAs in which clinical, virological and analytical data were prospectively included. We report on the data from 103 KT recipients who received DAAs. Results: The most commonly used DAAs combinations were sofosbuvir/ledipasvir (n = 59, 57%) and sofosbuvir + daclatasvir (n = 18, 17%). Ribavirin was used in 41% of patients. Sustained viral response after 12 weeks (SVR12) rate was 98%. Grade 2 or 3 anemia appeared in 14 (33%) of patients receiving ribavirin and in 9 (15%) without (p = 0.03). There were three episodes of acute humoral graft rejection. No patient discontinued therapy due to adverse events. Importantly, 57 (55%) patients required immunosuppression dose adjustment. Overall, there were no statistically significant differences in the mean level of serum creatinine, eGFR and proteinuria before and after treatment. Nonetheless, seventeen (16%) patients experienced renal dysfunction (increase in serum creatinine >25%) during antiviral therapy, of whom 65% were cirrhotic in comparison with only 29% cirrhotic patients who did not develop significant renal dysfunction (p = 0.004). Conclusions: Antiviral therapy with DAAs was highly efficacious and safe in KT recipients. Nevertheless, a non-negligible number of patients, most of them cirrhotic, developed mild allograft dys-function and a significant proportion of patients required immunosuppression dose adjustment, warranting a close follow-up during therapy. Lay summary: Infection by hepatitis C virus is often found in kidney transplant patients and its presence increases mortality and graft failure. We investigated the efficacy and safety of the new direct-acting hepatitis C antivirals in this population, in which previous information is scarce. Our data shows that, as occurs in the non-transplant setting, new anti-HCV antivirals are highly efficacious kidney transplant patients. Overall, this therapy is also quite safe, although worsening of renal function is observed in 16% of patients warranting a close follow-up observation of graft function during antiviral therapy. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.

Published
2017

20. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease

Author

Lens, S, Fernandez, I, Rodriguez-Tajes, S, Hontangas, V, Vergara, M, Forne, M, Calleja, JL, Diago, M, Llaneras, J, Llerena, S, Torras, X, Sacristan, B, Roget, M, Fernandez-Rodriguez, CM, Navascues, MC, Fuentes, J, Sanchez-Ruano, JJ, Simon, MA, Saez-Royuela, F, Baliellas, C, Morillas, R, and Forns, X

Abstract

OBJECTIVES: Interferon-free therapies have an improved safety and efficacy profile. However, data in elderly patients, who have frequently advanced liver disease, associated comorbidities, and use concomitant medications are scarce. The im of this study was to assess the effectiveness and tolerability of all-oral regimens in elderly patients in real-life clinical practice. METHODS: Retrospective analysis of hepatitis C virus (HCV) patients aged >= 65 years receiving interferon-free regimens within the Spanish National Registry (Hepa-C). RESULTS: Data of 1,252 patients were recorded. Of these, 955 (76%) were aged 65-74 years, 211 (17%) were aged 75-79 years, and 86 (7%) were aged >= 80 years at the start of antiviral therapy. HCV genotype-1b was predominant (88%) and 48% were previous non-responders. A significant proportion of patients had cirrhosis (922; 74%), of whom 11% presented decompensated liver disease. The most used regimens were SOF/LDV (33%), 3D (28%), and SOF/SMV (26%). Ribavirin was added in 49% of patients. Overall, the sustained virological response (SVR12) rate was 94% without differences among the three age categories. Albumin = 75 years (2.59 (1.16-5.83); P = 0.02) and albumin = 75 years) or those with advanced liver disease (albumin

Published
2017

22. Survival benefit of liver transplantation in Catalonia: A 2007–13 analysis

Author

Colmenero, J., primary, Lombardo, J., additional, Trota, N., additional, Crespo, G., additional, Bilbao, I., additional, Rafecas, A., additional, Xiol, X., additional, Castells, L., additional, Baliellas, C., additional, Ruiz, P., additional, Biggins, S., additional, Fondevila, C., additional, Tort, J., additional, and Navasa, M., additional

Published
2018
Full Text
View/download PDF

24. High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry

Author

Aranda, E.B., Mariño, Zoe, Calvo, S., Carrión, J.A., Fernández, I., García-Samaniego, J., Baliellas, C., Pascasio, J.M., Albillos, A., Carrillo, C.F., Castro-Iglesias, Ángeles, Planas, J.M.M., Giner, C.P., Palomares, J.J.M., Llaneras, J., Arenas, J., Fernández-Bermejo, M., Fernández, C., López, R.M.G., García, P.B., Romero-Gómez, Manuel, Sáez-Royuela, F., Aranda, E.B., Mariño, Zoe, Calvo, S., Carrión, J.A., Fernández, I., García-Samaniego, J., Baliellas, C., Pascasio, J.M., Albillos, A., Carrillo, C.F., Castro-Iglesias, Ángeles, Planas, J.M.M., Giner, C.P., Palomares, J.J.M., Llaneras, J., Arenas, J., Fernández-Bermejo, M., Fernández, C., López, R.M.G., García, P.B., Romero-Gómez, Manuel, and Sáez-Royuela, F.

Published
2017

25. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Author

Londoño, M.C., García-Buey, L., Mallolas, J., Barril, Guillermina, Ahumada, A., Riveiro-Barciela, M., Muñoz-Gómez, R., Roget, M., Serra, M.A., Devesa, M.J., Navascues, C., Baliellas, C., Aldamiz-Echevarría, T., Gutiérrez, M.L., Carmona, I., Polo-Lorduy, B., Bonet, L., García-Samaniego, J., Jiménez, M., Prieto, M., Moran, S., Castro-Iglesias, Ángeles, Delgado, M., Gea, F., Martín-Granizo, I., Montes, M., Morano, L., Castaño, M.A., De los Santos, I., Laguno, M., Losa, J.E., Montero, M., Rivero, A., Manzanares, A., De Álvaro, C., Londoño, M.C., García-Buey, L., Mallolas, J., Barril, Guillermina, Ahumada, A., Riveiro-Barciela, M., Muñoz-Gómez, R., Roget, M., Serra, M.A., Devesa, M.J., Navascues, C., Baliellas, C., Aldamiz-Echevarría, T., Gutiérrez, M.L., Carmona, I., Polo-Lorduy, B., Bonet, L., García-Samaniego, J., Jiménez, M., Prieto, M., Moran, S., Castro-Iglesias, Ángeles, Delgado, M., Gea, F., Martín-Granizo, I., Montes, M., Morano, L., Castaño, M.A., De los Santos, I., Laguno, M., Losa, J.E., Montero, M., Rivero, A., Manzanares, A., and De Álvaro, C.

Published
2017

26. Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort

Author

Riveiro-Barciela, M., Alonso, Sonia, Fernández, Inmaculada, Rincón, Diego, Real, Yolanda, Crespo, Javier, Gea, Francisco, Olveira, Antonio, Calleja, J.L., Polo-Lorduy, B., Carrión, J.A., Arenas, J., Devesa, M.J., Baliellas, C., Castro-Iglesias, Ángeles, Romero-Gómez, Manuel, Granados, R., Pascasio, J.M., Forns, Xavier, Turnes, Juan, Montero, J.L., Esteban, R., and Fernández-Rodríguez, Conrado M.

Subjects
ComputingMethodologies_GENERAL
Abstract

Poster abstract

Published
2016

27. Spontaneous bacterial empyem revisited

Author

Amador, A., primary, Berbel, D., additional, Cachero, A., additional, Dueñas, E., additional, García-Guix, M., additional, Salord, S., additional, Rota, R., additional, Baliellas, C., additional, Ardanuy, C., additional, Xiol, X., additional, and Castellote, J., additional

Published
2017
Full Text
View/download PDF

28. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Author

Londoño, M.-C., primary, Garcia-Buey, L., additional, Mallolas, J., additional, Barril, G., additional, Ahumada, A., additional, Riveiro-Barciela, M., additional, Muñoz-Gomez, R., additional, Roget, M., additional, Serra, M.A., additional, Devesa, M.J., additional, Navascues, C., additional, Baliellas, C., additional, Aldamiz-Echevarria, T., additional, Gutierrez, M.L., additional, Carmona, I., additional, Polo-Lorduy, B., additional, Bonet, L., additional, Garcia-Samaniego, J., additional, Jiménez, M., additional, Prieto, M., additional, Moran, S., additional, Castro, A., additional, Delgado, M., additional, Gea, F., additional, Martin-Granizo, I., additional, Montes, M., additional, Morano, L., additional, Castaño, M.A., additional, De los Santos, I., additional, Laguno, M., additional, Losa, J.E., additional, Montero, M., additional, Rivero, A., additional, Manzanares, A., additional, and De Alvaro, C., additional

Published
2017
Full Text
View/download PDF

29. High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry

Author

Aranda, E.B., primary, Mariño, Z., additional, Calvo, S., additional, Carrión, J.A., additional, Fernández, I., additional, García-Samaniego, J., additional, Baliellas, C., additional, Pascasio, J.M., additional, Albillos, A., additional, Carrillo, C.F., additional, Iglesias, A.C., additional, Planas, J.M.M., additional, Giner, C.P., additional, Palomares, J.J.M., additional, Llaneras, J., additional, Arenas, J., additional, Fernández-Bermejo, M., additional, Fernández, C., additional, Lopez, R.M.G., additional, García, P.B., additional, Romero-Gómez, M., additional, and Sáez-Royuela, F., additional

Published
2017
Full Text
View/download PDF

30. Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy

Author

Lens, S., primary, Fernandez, I., additional, Rodríguez-Tajes, S., additional, Vergara, M., additional, Forné, M., additional, Calleja, J.L., additional, Diago, M., additional, Llaneras, J., additional, Llerena, S., additional, Torras, X., additional, Sacristan, B., additional, Roget, M., additional, Fernández-Rodríguez, C.M., additional, Navascués, C., additional, Fuentes, J., additional, Sanchez-Ruano, J.J., additional, Simón, M.A., additional, Saez-Royuela, F., additional, Baliellas, C., additional, Morillas, R.M., additional, and Forns, X., additional

Published
2017
Full Text
View/download PDF

31. Efficacy and safety of HCV-treatment with direct-acting antiviral agents interferon-free, in patients with severe renal impairment in clinical practice

Author

Cabezas, Joaquín, Londoño, M.C., Llerena, S., Muñoz, R., Baliellas, C., Buti, M., Pascasio, J.M., Sáez-Royuela, F., García-Samaniego, J., Vega, J. de la, Sánchez-Pobre, P., Álvarez-Navascues, C., Carrión, J.A., Gea, F., Morillas, R.M., Fernández-Bermejo, M., Castro-Iglesias, Ángeles, Rivero, M., Fernández, J.R., Berenguer, M., Moreno, J.J., Rincón, D., Calleja, J.L., Crespo, J., Cabezas, Joaquín, Londoño, M.C., Llerena, S., Muñoz, R., Baliellas, C., Buti, M., Pascasio, J.M., Sáez-Royuela, F., García-Samaniego, J., Vega, J. de la, Sánchez-Pobre, P., Álvarez-Navascues, C., Carrión, J.A., Gea, F., Morillas, R.M., Fernández-Bermejo, M., Castro-Iglesias, Ángeles, Rivero, M., Fernández, J.R., Berenguer, M., Moreno, J.J., Rincón, D., Calleja, J.L., and Crespo, J.

Published
2016

32. Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4

Author

Mariño, Zoe, Pascasio-Acevedo, Juan M., Sánchez-Antolín, Gloria, Baliellas, C., Prieto, M., Moreno, J.M., Carrión, J.A., Fernández, I., Gómez, A., Montero, J.L., Castro-Iglesias, Ángeles, Pascual, Sonia, Cabezas, Joaquín, Arencibia, Ana C., Calleja, J.L., Sánchez Ruano, Juan José, Castells, Lluis, Albillos, A., Romero-Gómez, Manuel, García-Samaniego, J., Narváez, Isidro, Serrano, T., Giráldez, Álvaro, Xiol, X., Hontagas, V., Cuervas-Mons Martínez, Valentín, Crespo, J., Forns, Xavier, Mariño, Zoe, Pascasio-Acevedo, Juan M., Sánchez-Antolín, Gloria, Baliellas, C., Prieto, M., Moreno, J.M., Carrión, J.A., Fernández, I., Gómez, A., Montero, J.L., Castro-Iglesias, Ángeles, Pascual, Sonia, Cabezas, Joaquín, Arencibia, Ana C., Calleja, J.L., Sánchez Ruano, Juan José, Castells, Lluis, Albillos, A., Romero-Gómez, Manuel, García-Samaniego, J., Narváez, Isidro, Serrano, T., Giráldez, Álvaro, Xiol, X., Hontagas, V., Cuervas-Mons Martínez, Valentín, Crespo, J., and Forns, Xavier

Published
2016

33. Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort

Author

Alonso, S., Riveiro-Barciela, M., Fernández, I., Rincón, D., Real, Y., Llerena, S., Gea, F., Olveira, A., Fernández-Carrillo, C., Polo, B., Carrión, J.A., Gómez, A., Devesa, M.J., Baliellas, C., Castro-Iglesias, Ángeles, Ampuero, J., Granados, R., Pascasio, J.M., Rubín, A., Salmerón, J., Badia, E., Planas, J.M.M., Lens, S., Turnes, J., Montero, J.L., Buti, M., Esteban, R., Fernández-Rodríguez, C.M., Alonso, S., Riveiro-Barciela, M., Fernández, I., Rincón, D., Real, Y., Llerena, S., Gea, F., Olveira, A., Fernández-Carrillo, C., Polo, B., Carrión, J.A., Gómez, A., Devesa, M.J., Baliellas, C., Castro-Iglesias, Ángeles, Ampuero, J., Granados, R., Pascasio, J.M., Rubín, A., Salmerón, J., Badia, E., Planas, J.M.M., Lens, S., Turnes, J., Montero, J.L., Buti, M., Esteban, R., and Fernández-Rodríguez, C.M.

Abstract

[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014‐October 2015). In total, 208 patients were included: 98 (47%) treatment‐experienced, 42 (20%) decompensated and 55 (27%) MELD score >10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count <75×10E9/mL (RR: 3.50, P=.019). In patients with MELD <10, type of NS5A inhibitor did not impact on SVR12 (94% vs 97%; adjusted RR: 0.49). Thirteen patients (6.3%) had serious adverse events, including three deaths (1.4%) and one therapy discontinuation (0.5%), higher in decompensated patients (16.7% vs 3.6%, P<.006). In patients with GT3 infection and cirrhosis, SVR12 rates were high with both SOF+DCV and SOF/LDV, with few serious adverse events.

Published
2016

34. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

Author

Alonso, S., primary, Riveiro-Barciela, M., additional, Fernandez, I., additional, Rincón, D., additional, Real, Y., additional, Llerena, S., additional, Gea, F., additional, Olveira, A., additional, Fernandez-Carrillo, C., additional, Polo, B., additional, Carrión, J. A., additional, Gómez, A., additional, Devesa, M. J., additional, Baliellas, C., additional, Castro, Á., additional, Ampuero, J., additional, Granados, R., additional, Pascasio, J. M., additional, Rubín, A., additional, Salmeron, J., additional, Badia, E., additional, Planas, J. M. M., additional, Lens, S., additional, Turnes, J., additional, Montero, J. L., additional, Buti, M., additional, Esteban, R., additional, and Fernández-Rodríguez, C. M., additional

Published
2016
Full Text
View/download PDF

35. Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4

Author

Mariño, Z., primary, Pascasio, J.M., additional, Sánchez-Antolin, G., additional, Baliellas, C., additional, Prieto, M., additional, Moreno, J.M., additional, Carrión, J.A., additional, Fernández, I., additional, Gomez, A., additional, Montero, J.L., additional, Castro, A., additional, Pascual, S., additional, Cabezas, J., additional, Arencibia C. Del, A., additional, Calleja, J.L., additional, Sanchez-Ruano, J.J., additional, Castells, L., additional, Albillos, A., additional, Romero, M., additional, García-Samaniego, J., additional, Narváez, I., additional, Serrano, T., additional, Giraldez, A., additional, Xiol, X., additional, Hontangas, V., additional, Cuervas-Mons, V., additional, Crespo, J., additional, and Forns, X., additional

Published
2016
Full Text
View/download PDF

38. Efficacy and Tolerability of Interferon-Free Antiviral Therapy in Kidney Transplant (KT) Recipients with Chronic Hepatitis C: Real-Life Data from the Spanish National Registry (HEPA-C)

Author

Londoño, M.-C., primary, Fernández, I., additional, Muñoz-Gómez, R., additional, Pascasio, J.-M., additional, Baliellas, C., additional, Polanco, N., additional, Esforzado, N., additional, Prieto, M., additional, Castells, L., additional, Crespo, J., additional, Calleja, J.-L., additional, Gea, F., additional, and Forns, X., additional

Published
2016
Full Text
View/download PDF

39. Ledipasvir/Sofosbuvir for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Spanish Multicentre Experience

Author

Prieto, M., primary, Fernández, I., additional, Londoño, M.-C., additional, Abradelo, M., additional, Pascasio, J.M., additional, Gea, F., additional, Rincón, D., additional, Cuervas-Mons, V., additional, Crespo, G., additional, Montero, J.L., additional, Hontangas, V., additional, Baliellas, C., additional, Sousa, J.M., additional, García, M., additional, Pascual, S., additional, Pons, J.A., additional, Castells, L., additional, Testillano, M., additional, Jimenez, M., additional, Otero, A., additional, Molina, E., additional, González, A., additional, Nogueras, F., additional, González-Dieguez, L., additional, Lorente, S., additional, Sánchez-Antolín, G., additional, Herrero, J.I., additional, and Casafont, F., additional

Published
2016
Full Text
View/download PDF

40. Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry

Author

Fernández-Carrillo, C., primary, Lens, S., additional, Llop, E., additional, Pascasio, J.M., additional, Fernández, I., additional, Baliellas, C., additional, Crespo, J., additional, Buti, M., additional, Castells, L., additional, Romero-Gómez, M., additional, Pons, C., additional, Moreno, J.M., additional, Albillos, A., additional, Fernández-Rodríguez, C., additional, Prieto, M., additional, Fernández-Bermejo, M., additional, García-Samaniego, J., additional, Carrión, J.A., additional, de la Mata, M., additional, Badia, E., additional, Salmerón, J., additional, Herreros, J.I., additional, Salcedo, M., additional, Moreno, J.J., additional, Turnes, J., additional, Granados, R., additional, Blé, M., additional, and Calleja, J.L., additional

Published
2016
Full Text
View/download PDF

42. Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice

Author

Cabezas, J., primary, Londoño, M.C., additional, Llerena, S., additional, Muñoz, R., additional, Baliellas, C., additional, Buti, M., additional, Pascasio, J.M., additional, Saez-Royuela, F., additional, García-Samaniego, J., additional, de la Vega, J., additional, Sanchez-Pobre, P., additional, Alvarez-Navascues, C., additional, Carrión, J.A., additional, Gea, F., additional, Morillas, R.M., additional, Fernandez-Bermejo, M., additional, Castro, A., additional, Rivero, M., additional, Fernandez, J.R., additional, Berenguer, M., additional, Moreno, J.J., additional, Rincon, D., additional, Calleja, J.L., additional, and Crespo, J., additional

Published
2016
Full Text
View/download PDF

43. Endoscopic radiofrequency ablation for APC refractory gastric antral vascular ectasia using the HALO90 system in a kidney transplant candidate

Author

Ibáñez-Sanz G, Rivas L, Melilli E, Jordi Guardiola, Baliellas C, and Jb, Gornals

Subjects
Male, Argon Plasma Coagulation, Cirurgia, Ronyó, Middle Aged, Kidney, Kidney Transplantation, Ablació percutània, surgical procedures, operative, Gastroscopy, Catheter Ablation, Humans, Kidney Failure, Chronic, Catheter ablation, Surgery, lcsh:Diseases of the digestive system. Gastroenterology, lcsh:RC799-869, Gastric Antral Vascular Ectasia
Abstract

Gastric antral vascular ectasia (GAVE) is a rare but important cause of gastrointestinal bleeding and anemia. Endoscopic ablation, such as argon plasma coagulation (APC), is usually successful, but treatment-refractory cases do occur. Recently, radiofrequency ablation (RFA) has been described as an alternative therapeutic option for GAVE, or actinic proctitis, with positive results and minor complications.

Published
2015

47. Secondary bacterial peritonitis in cirrhosis: A retrospective study of clinical and analytical characteristics, diagnosis and management

Author

Soriano, G, Castellote, J, Alvarez, C, Girbau, A, Gordillo, J, Baliellas, C, Casas, M, Pons, C, Roman, EM, Maisterra, S, Xiol, X, and Guarner, C

Subjects
Secondary peritonitis, Cirrhosis, Surgery
Abstract

Background & Aims: Secondary bacterial peritonitis in cirrhotic patients is an uncommon entity that has been little reported. Our aim is to analyse the frequency, clinical characteristics, treatment and prognosis of patients with secondary peritonitis in comparison to those of patients with spontaneous bacterial peritonitis (SBP). Methods: Retrospective analysis of 24 cirrhotic patients with secondary peritonitis compared with 106 SBP episodes. Results: Secondary peritonitis represented 4.5% of all peritonitis in cirrhotic patients. Patients with secondary peritonitis showed a significantly more severe local inflammatory response than patients with SBP. Considering diagnosis of secondary peritonitis, the sensitivity of Runyon's criteria was 66.6% and specificity 89.7%, Runyon's criteria and/or polymicrobial ascitic fluid culture were present in 95.6%, and abdominal computed tomography was diagnostic in 85% of patients in whom diagnosis was confirmed by surgery or autopsy. Mortality during hospitalization was higher in patients with secondary peritonitis than in those with SBP (16/24, 66.6% vs. 28/106, 26.4%) (p < 0.001). There was a trend to lower mortality in secondary peritonitis patients who underwent surgery (7/13, 53.8%) than in those who received medical treatment only (9/11, 81.8%) (p = 0.21). Considering surgically treated patients, the time between diagnostic paracentesis and surgery was shorter in survivors than in non-survivors (3.2 +/- 2.4 vs. 7.2 +/- 6.1 days, p = 0.31). Conclusions: Secondary peritonitis is an infrequent complication in cirrhotic patients but mortality is high. A low threshold of suspicion on the basis of Runyon's criteria and microbiological data, together with an aggressive approach that includes prompt abdominal computed tomography and early surgical evaluation, could improve prognosis in these patients. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Published
2010

48. SAT-266 - Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy

Author

Lens, S., Fernandez, I., Rodríguez-Tajes, S., Vergara, M., Forné, M., Calleja, J.L., Diago, M., Llaneras, J., Llerena, S., Torras, X., Sacristan, B., Roget, M., Fernández-Rodríguez, C.M., Navascués, C., Fuentes, J., Sanchez-Ruano, J.J., Simón, M.A., Saez-Royuela, F., Baliellas, C., Morillas, R.M., and Forns, X.

Published
2017
Full Text
View/download PDF

49. SAT-226 - Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study

Author

Londoño, M.-C., Garcia-Buey, L., Mallolas, J., Barril, G., Ahumada, A., Riveiro-Barciela, M., Muñoz-Gomez, R., Roget, M., Serra, M.A., Devesa, M.J., Navascues, C., Baliellas, C., Aldamiz-Echevarria, T., Gutierrez, M.L., Carmona, I., Polo-Lorduy, B., Bonet, L., Garcia-Samaniego, J., Jiménez, M., Prieto, M., Moran, S., Castro, A., Delgado, M., Gea, F., Martin-Granizo, I., Montes, M., Morano, L., Castaño, M.A., De los Santos, I., Laguno, M., Losa, J.E., Montero, M., Rivero, A., Manzanares, A., and De Alvaro, C.

Published
2017
Full Text
View/download PDF

50. THU-275 - High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry

Author

Aranda, E.B., Mariño, Z., Calvo, S., Carrión, J.A., Fernández, I., García-Samaniego, J., Baliellas, C., Pascasio, J.M., Albillos, A., Carrillo, C.F., Iglesias, A.C., Planas, J.M.M., Giner, C.P., Palomares, J.J.M., Llaneras, J., Arenas, J., Fernández-Bermejo, M., Fernández, C., Lopez, R.M.G., García, P.B., Romero-Gómez, M., and Sáez-Royuela, F.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results